Viva in Vitro Projects

Sepsis is the leading cause of hospital death. According to the WHO, sepsis affects more than 50 million people every year, causing the death of more than 11 million people. Almost half of them are children.

Viva In Vitro is focused on the development of its first compact hospital laboratory device for the rapid diagnosis and accurate prognosis of abdominal sepsis as the leading cause of hospital mortality, human suffering, resource consumption and expenditure in Intensive Care Units (ICU). But it does not renounce to collaborations, out-licensing or joint developments together with pharmaceutical companies or medical device manufacturers for the development of novel therapies or diagnostic devices in various indications.

Prototype of a compact device for hospital use for the prognosis of abdominal sepsis

Viva In Vitro intends to start testing its beta prototype by the end of 2022. This will allow to verify the usability conditions in realistic conditions and ensure final design specifications meet the expectations of the numerous users and potential buyers in hospitals throughout Spain who were consulted before starting the development of the product. The goal is to get the definitive prototype by the end of 2023.

See project

Development of a microfluidic solution

The first step towards a compact and easy-to-use device is to determine a microfluidic solution that makes an analysis on a small sample of whole blood possible, that reduces the number of steps required and that makes to obtain the data feasible, reliable and economical. Viva In Vitro is already working on it hand in hand with some of the best European experts in microfluidic solutions for medical devices.

See project

Spedi-Test Clinical Proof Of Concept

SPEDI-TEST introduces a novel and unique solution for septic shock affected patients. The IMIB’s Molecular Inflammation Group is the first-ever clinical or biochemical research group that has detected that monocytes of human patients present early an inability to activate the nlrp3 inflammasome within the first 24 hours of the inflammatory response in sepsis, and this has a cause-effect relation with more than 80% of deaths in such patients. Since this discovery, the group has developed, and exclusively licensed it out to Viva In Vitro, a novel in vitro prognostic method for the rapid—less than 4 hours—detection of this early inability to activate the nlrp3 inflammasome, as a biomarker not only of sepsis but of the most likely evolution of the septic patient.

See project